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COST-OF-ILLNESS STUDY OF PATIENTS WITH 
ALLERGIC ASTHMA AND SEASONAL ALLERGIC 
RHINITIS IN GERMANY
Quednau K1, Schramm B2, Ehlken B2, Smala A2, Naujoks C3, 
Berger K2
1Novartis Pharma GmbH, Nuremberg, Germany; 2MERG - 
Medical Economics Research Group, Munich, Germany; 
3Novartis Pharma AG, Basel, Switzerland
OBJECTIVES: To evaluate the cost-of-illness of moder-
ate to severe allergic asthma and/or seasonal allergic rhin-
itis in Germany from the third-party payers’ and the pa-
tients’ perspective.
METHODS: Twenty pneumologists and 16 pediatricians
(office-based) participated. Five hundred patients (276
children) suffering from moderate to severe asthma and/
or seasonal allergic rhinitis (SAR) were included in this
retrospective, cross-sectional cost-of-illness study. Infor-
mation such as demographic characteristics, consulta-
tions, emergency visits, hospitalizations, rehabilitations,
out-of-pocket-expenditures such as OTC-medication, co-
payment or house refurbishment and absence from work
was collected with a standardized patient questionnaire.
Resource utilization of outpatient care was acquired from
305 patients’ records. Direct and indirect costs were con-
sidered.
RESULTS: Overall, annual costs per patient rise with
increasing severity of allergic asthma and in combina-
tion with seasonal allergic rhinitis. The average, annual,
per-patient cost for children with SAR is 3071 DEM
(€1566), for adolescents, 1509 DEM (€770), and for
adults, 2234 DEM (€1139). Annual per-patient costs
for severe asthma plus SAR increase to 14.431 DEM
(€7360) for children, to 17.059 DEM (€8700) for ado-
lescents, and to 18163 DEM (€9263) for an adult pa-
tient. From the third-party payers’ perspective, the main
cost drivers are medications, hospitalizations and rehabil-
itation. Additionally, around 6% of the adults retired
early due to asthma or asthma/SAR. From the patients’
perspective, house refurbishment was the most relevant
cost factor. For children and adolescents, direct costs are
responsible for 60 to 78% of the expenditures, whereas
for adults, the indirect costs are responsible for 58% of
the expenditures.
CONCLUSIONS: The financial burden due to allergic
asthma and/or seasonal allergic rhinitis from the third-
party payers’ perspective is comparable to other chronic
diseases such as coronary heart disease (CHD) or diabe-
tes mellitus type 2 in Germany. For patients, their rela-
tives and society, large additional costs accrue.
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VARIATIONS IN COVERAGE FOR EFFECTIVE 
SERVICES FOR ASTHMA: IMPACT OF
NATIONAL GUIDELINES
Hanlon JT, Wheeler J, Fendrick AM
University of Michigan, Ann Arbor, MI, USA
In 1997, the US National Institutes of Health issued the sec-
ond Guidelines for the Diagnosis and Management of
Asthma, to further improve the quality of care for asthma pa-
tients. Coverage of the interventions recommended in these
guidelines is imperative if optimal utilization is to occur.
OBJECTIVE: To quantify and compare coverage for
asthma services recommended by NIH guidelines among
statewide health-insurance plans.
METHODS: A survey of asthma services covered for the
year 2000 was administered to Quality Improvement
Managers of 28 managed care providers in the state of
Michigan. Management strategies included: inpatient and
outpatient hospital care; physician services; disease man-
agement services; patient education; prescription medica-
tions; medical devices, and emergency and urgent care
visits. Coverage was further delineated into private payer
benefits and Medicare (elderly) and Medicaid (poor) re-
cipients’ benefits. Additional data were collected via the
Internet on fee-for-service reimbursement rates.
RESULTS: Coverage of guideline-recommended services
varied within and among health plans. For example
Medicare emergency room visit coverage ranged from
20% of the facility costs to a $25 per visit charge. Alter-
natively, one provider offers variable rates for the same
service based on purchaser contract. Additionally, ser-
vices offered vary widely among plans. One facility of-
fered a fully implemented asthma case-management ser-
vice while another reported that no education or disease
management program was covered. The range of asthma-
care interventions supported by the health plans will be
fully described.
CONCLUSION: Significant variations in coverage exist
among health plans for asthma interventions. To ensure
optimal quality of care for asthma sufferers, health plans
should prioritize coverage for those interventions recom-
mended in evidence-based guidelines. Insurers and pro-
viders should examine and implement guidelines in order
to improve availability of proposed standards of asthma-
care management.
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EFFECTS OF DISEASE MANAGEMENT ON 
QUALITY OF LIFE IN PATIENTS WITH ASTHMA
Greiner W, Graf V.D. Schulenburg J-M, Blanke M
University of Hannover, Hannover, Germany
OBJECTIVES: This study deals with an economic evalu-
ation of a Disease Management Program for asthma with
the help of an electronic control instrument for Home-
Monitoring of the patient. Research was made on the im-
provement in quality of life as well as on the cost savings.
METHODS: One hundred twelve adult patients with
asthma of varying severities were divided randomly into
two groups. The patients are all members of a large Ger-
man health insurance group in the Bundesland Rhein-
land-Pfalz. The first group received an extensive Disease
Management Program with electronic Home-Monitor-
ing, while the control group was treated further by their
